StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Fri, 23 Oct 2026 07:37:46 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $39.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented: "New biomarker findings complement previously reported visual and retinal benefits from privosegtor. Yesterday, Oculis reported new biomarker analyses from the Phase 2 ACUITY trial of privosegtor in patients with acute optic neuritis (ON). Post-onset increases in plasma neurofilament light chain (NfL), a marker of neuroaxonal injury, and glial fibrillary acidic protein (GFAP), a marker of reactive astrocytic activation, were lower with privosegtor than placebo, particularly at early timepoints following disease onset. These findings complement the previously reported 18-letter benefit

Oculis reports biomarker data from Phase 2 trial of Privosegtor

Thu, 22 Oct 2026 02:00:19 -0400

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) announced new biomarker data from its Phase 2 ACUITY trial of Privosegtor in patients with optic neuritis, according to a company press release dated October 22, 2026.

The analysis found that increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels were reduced in patients receiving Privosegtor compared with placebo, particularly at early timepoints following acute optic neuritis onset.

At Day 5, mean plasma NfL increases were higher in the placebo group than in the Privosegtor group. NfL levels remained stable in the Privosegtor group through Month 6, while placebo

Oculis reports Phase 2 biomarker data for optic neuritis drug

Thu, 22 Oct 2026 02:00:16 -0400

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) announced new biomarker data from its Phase 2 ACUITY trial of Privosegtor, an investigational drug for optic neuritis, showing reductions in two blood-based markers of nerve damage compared with placebo.

The analysis found that increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were lower in patients treated with Privosegtor than in the placebo group, particularly at early timepoints following acute optic neuritis onset. NfL levels remained stable in the Privosegtor group through Month 6, while placebo group levels stayed elevated above baseline at Month 1 before returning to

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Thu, 22 Oct 2026 02:00:00 -0400

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo

Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis

Biomarker results support previously reported functional (LCVA) +18-letter gains and structural retinal preservation at Month 3, reinforcing Privosegtor’s development for acute optic neuritis and acute multiple sclerosis relapses

ZUG, Switzerland, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Thu, 22 Oct 2026 02:00:00 -0400

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo

Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis

ZUG, Switzerland, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Thu, 22 Oct 2026 02:00:00 -0400

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo

Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis

ZUG, Switzerland — October 22, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Thu, 22 Oct 2026 02:00:00 -0400

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo

Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis

ZUG, Switzerland — October 22, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical

H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Wed, 21 Oct 2026 06:50:57 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $39.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented: "PREDICT-1 randomization complete; topline data expected around end-2026. Yesterday, Oculis announced the completion of patient randomization in the PREDICT-1 genotype-based registrational trial of licaminlimab as a precision medicine for dry eye disease (DED). Of note, randomization is complete with 176 patients enrolled in this multicenter, double-masked, vehicle-controlled study, which 2/3 of patients having the specified TNFR1 genotype. The primary endpoint is the change from baseline to Day 29 in the global ocular discomfort severity score in patients with the

Oculis to present Privosegtor biomarker data at MS conference

Tue, 20 Oct 2026 02:00:16 -0400

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) announced it will present biomarker analyses from its Phase 2 ACUITY trial of Privosegtor at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, Canada, running October 21-23, 2026.

The presentation, titled "Effect of Privosegtor on Plasma Neurofilament-Light and Glial Fibrillary Acidic Protein Levels in the Phase 2 ACUITY Trial in Optic Neuritis," is scheduled for October 22, 2026, from 4:30 to 6:30 p.m. EDT at the Metro Toronto Convention Centre. Céline Louapre, M.D., Ph.D., of Pitié-Salpêtrière Hospital, the principal investigator of the ACUITY trial, will deliver the presentation.

The data evaluate plasma neurofilament light chain

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Tue, 20 Oct 2026 02:00:00 -0400

Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation

ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at the 10^th Joint ACTRIMS-ECTRIMS Meeting (MSToronto 2026), on October 21-23, 2026, in Toronto, Canada.

The presentation will unveil new analyses evaluating circulating neuroaxonal and neuroinflammatory

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Tue, 20 Oct 2026 02:00:00 -0400

Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation

The presentation will unveil new analyses evaluating circulating neuroaxonal and neuroinflammatory

Oculis completes enrollment in PREDICT-1 dry eye disease trial

Mon, 19 Oct 2026 06:03:08 -0400

Oculis Holding AG (Nasdaq: OCS) announced it has completed enrollment in its PREDICT-1 clinical trial evaluating Licaminlimab, a topical eye drop containing a TNFα inhibitor, for the treatment of dry eye disease (DED) based on patient genotype.

A total of 176 patients were enrolled in the randomized, multi-site, double-blind, vehicle-controlled study. Approximately two-thirds of enrolled patients carry a specific TNFR1 genetic variant that has been associated with increased clinical response in prior phase 2 studies. The trial's primary endpoint is the change from baseline to day 29 in total ocular discomfort score among patients with the specified TNFR1 genotype. The same

Oculis completes enrollment in PREDICT-1 dry eye disease trial

Mon, 19 Oct 2026 06:03:08 -0400

Oculis completes enrollment in dry eye disease trial PREDICT-1

Mon, 19 Oct 2026 06:02:56 -0400

Oculis Holding AG (Nasdaq: OCS) announced the completion of patient randomization in its PREDICT-1 registrational trial, evaluating licaminlimab for the treatment of dry eye disease (DED) in patients with a specific TNFR1 genetic variant.

The trial enrolled 176 patients across a randomized, multicenter, double-masked, vehicle-controlled study. Approximately two-thirds of enrolled patients carry the target TNFR1 genetic variant. The primary endpoint is the change from baseline at Day 29 in the global ocular discomfort severity score among patients with the specified genotype. The same measure will be evaluated in the overall study population as a key secondary endpoint.

Oculis said it expects to

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

Mon, 19 Oct 2026 02:00:00 -0400

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials

Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a potential first-in-class precision medicine for an estimated 1.5+ million patients in the U.S. with moderate-to-severe TNFR1-mediated dry eye disease (DED)^1-4, addressing a critical unmet need in a historically heterogeneous indication.

Key Milestone on Track: Topline data from this first-ever genotype-guided registrational trial in DED are anticipated around year-end 2026

ZUG, Switzerland, October 19, 2026 -- Oculis Holding AG (Nasdaq:

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

Mon, 19 Oct 2026 02:00:00 -0400

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials

Key Milestone on Track: Topline data from this first-ever genotype-guided registrational trial in DED are anticipated around year-end 2026

ZUG, Switzerland, October 19, 2026 -- Oculis Holding AG (Nasdaq:

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Mon, 19 Oct 2026 02:00:00 -0400

Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum.

Nákvæmnismeðferðarnálgun á stórum markaði: Licaminlimab gæti orðið fyrsta nákvæmnislyfjameðferðin sinnar tegundar fyrir rúmlega 1,5 milljón sjúklinga í Bandaríkjunum sem áætlað er að séu með miðlungs til alvarlegan TNFR1-miðlaðan augnþurrk (e. Dry Eye Disease, DED)^1-4, og mætt þannig brýnni óuppfylltri þörf á sviði sem í gegnum tíðina hefur einkennst af ólíkum sjúklingahópum.

Mikilvægur áfangi á áætlun: Gert er ráð fyrir að fyrstu niðurstöður (e. topline data)

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Mon, 19 Oct 2026 02:00:00 -0400

Mikilvægur áfangi á áætlun: Gert er ráð fyrir að fyrstu niðurstöður (e. topline data)

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Wed, 07 Oct 2026 01:59:00 -0400

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Wed, 07 Oct 2026 01:59:00 -0400

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on October 1, 2026.

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

Form 6-K Oculis Holding AG For: Sep 30

Wed, 30 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260930/27129360.html